Radezolid

Drug Profile

Radezolid

Alternative Names: RX-01667; Rx-01_667; RX-103; RX-1741

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Rib-X Pharmaceuticals
  • Developer Melinta Therapeutics; Unknown
  • Class Antibacterials; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia; Gram-positive infections; Skin and soft tissue infections
  • Preclinical Acne

Most Recent Events

  • 28 Feb 2017 Melinta Therapeutics plans a phase I trial for Acne in USA (Topical)
  • 28 Feb 2017 The US FDA accepts an IND application for Radezolid (Topical) for Acne
  • 25 Jun 2015 Phase-II development is ongoing for Community-acquired pneumonia and Skin and soft tissue infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top